Skip to content
Screener

Charles River Laboratories CRL Investing Cash Flow

Investing Cash Flow at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
-$366.2M-289%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$8.6M-19.5%
Sotera Health logo
Sotera HealthSHC
-$43.3M-38.6%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$11.09M+117%
Fortrea Holdings Inc. logo
Fortrea Holdings Inc.FTRE
-$7M—
Revvity logo
RevvityRVTY
-$78.27M-1,127%

Other financials

Income statement

See full
Revenue$1.0B-2.7%
Gross profit$349.0M-3.5%
Operating income$119.9M+19.7%
Net income-$1.5M-103%
EPS (diluted)-$0.03-103%

Balance sheet

See full
Cash & equivalents$240.6M+30.2%
Total debt$3.0B+8.1%
Total equity$2.8B-15.3%
Total assets$7.5B-0.4%

Cash flow

See full
Operating cash flow$179.7M-12.2%
CapEx$31.1M-11.9%
Free cash flow$148.6M-12.2%

Valuation

See full
Market cap$12.56B+70.1%
Enterprise value$15.36B+53.4%
P/S3.1×+1.3×

Profitability

See full
Gross margin84.7%—
Operating margin13%-2.4pp
Net margin-6%—
FCF margin9.3%-5.1pp

Returns & leverage

See full
Return on equity-7.7%—
Debt / equity1.1×+0.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Charles River Laboratories’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:14 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001100682-26-000038
Line itemThree Months Ended / March 28, 2026Three Months Ended / March 29, 2025
Proceeds from sale of investments2,9221,602
Proceeds from sale of businesses and assets, net60,09617,441
Other, net(1,457)104
Net cash used in investing activities(407,845)(45,479)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility912,462416,341
Payments on long-term debt, revolving credit facility, and finance lease obligations(355,676)(149,394)
Proceeds from exercises of stock options1,223—

Item 1. Financial Statements

FAQ

What is Charles River Laboratories's investing cash flow?
Charles River Laboratories (CRL) reported investing cash flow of -$407.85M in Q1 2026.
How has Charles River Laboratories's investing cash flow changed year-over-year?
Charles River Laboratories's investing cash flow decreased by 796.8% year-over-year, from -$45.48M to -$407.85M.
What is the long-term trend for Charles River Laboratories's investing cash flow?
Over 4 years (2021 to 2025), Charles River Laboratories's investing cash flow has grown at a -38.3% compound annual growth rate (CAGR), from -$1.45B to -$209.32M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Charles River Laboratories's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude